Wall Street Analyst Upgrade Mesoblast Ltd ADR [MESO]. What else is Wall St. saying
Mesoblast Ltd ADR [NASDAQ: MESO] closed the trading session at $5.01. The company report on March 25, 2024 at 10:34 PM that United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission